Low Risk of Side-effects and Non-toxic Nature to Drive Global Market for Peptide Drugs

Published Date : Jun 24, 2016

Peptides are biomolecules that have unique pharmacological properties compared to large proteins and small molecule drugs. Peptides play an important role in synchronizing intercellular communications and modulating a number of cellular functions. Scientists say that the medical world can significantly benefit from peptides and the more they are utilized in the production of medicines, the more safe and specific drugs can be manufactured.

The several benefits of peptides have been realized by the pharmaceutical industry in the past few years and several peptide drugs are entering the market at a steady pace. The market has witnessed significant traction in the past few years, however, only a few peptide drugs entered clinical trials. Currently, several hundreds of peptide drugs enter clinical trials and are released in the market for treating a variety of ailments.

The global peptide market has started attaining maturity and the global population is becoming more receptive of the several potential benefits of peptides against a number of medical challenges. The major demand for peptide drugs is found in specialty medical areas such as oncology, cardiovascular conditions, metabolic diseases, and infectious diseases. Nevertheless, the demand for peptide drugs has also substantially increased on the fronts such as hematology and endocrinology. 

The major benefits of peptide drugs are a much reduced risk of side-effects and their non-toxic nature. As peptide drug molecules and the parent molecules they are derived from are closely related, peptide drugs are known to pose little or no harm to the patients by virtue of undesired side effects. Side-effects caused by peptide drugs, if any, are mostly caused due to dosage-related or some kind of local reactions. So in general, no serious immune responses are known to result from peptide drugs.

Also, as peptide drugs are manufactured from substances that are naturally occurring and are metabolically tolerable amino acids, they are usually non-toxic. All these factors are resulting in the introduction of a relatively larger number of peptide drugs as compared to the past in the market.